Skip to main content

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

Enrolling by invitation · Phase 3 · NCT04905693

Conditions: Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis

At a glance

Research payments reported, 2025
$4.8M
U.S. investigators named
87
Sites paid
81
Planned or actual enrollment
1,850

About the trial

Sponsor
United Therapeutics
Tested
Inhaled Treprostinil (drug), Treprostinil Ultrasonic Nebulizer (device)
Dates
Started 2022-09-06; completion 2029-12
Results posted
Not yet

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

From ClinicalTrials.gov, last updated 2026-10-19. Full record, eligibility and contacts (opens in a new tab)

Industry funding

United Therapeutics Corporation reported $4.8M in research payments for this study in 2025 (1,439 payments).

Products named: Tyvaso

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.